Despite advances in prevention, diagnosis and treatment of tuberculosis and human immunodeficiency virus (HIV), tuberculosis remains the leading cause of death and illness among people living with HIV. In 2015, an estimated 1.2 million of the people who developed tuberculosis disease worldwide were HIV positive, and tuberculosis was the direct cause of at least one third of HIV related deaths. The 2015 “Treat All” strategy requires that everyone with HIV is offered antiretroviral therapy (ART) as soon as they are diagnosed.
drug-resistant tuberculosis (DR-TB)
High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa
Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study
Emerging superbugs that can resist even the most powerful antibiotics and medical treatments present one of the biggest global health threats in history.
When manifested in a simple throat infection, a lingering stomach bug or a serious disease like tuberculosis, resistance to medicine is tremendously threatening. Global development partners must move faster to contain the threat of antimicrobial resistance before it escalates to claim millions of lives around the world.
TB partners, patients ask: How does a bacterium responsible for nearly a third of drug-resistance deaths not make list of R&D priority pathogens?
Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics
The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments. To date, the selection of pathogens for R&D activities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, and availability of specific technologies.
Severe adverse events during second-line tuberculosis treatment in the context of high HIV co-infection in South Africa: a retrospective cohort study
According to the World Health Organization, South Africa ranks as one of the highest burden of TB, TB/HIV co-infection, and drug-resistant TB (DR-TB) countries. DR-TB treatment is complicated to administer and relies on the use of multiple toxic drugs, with potential for severe adverse drug reactions. We report the occurrence of adverse events (AEs) during a standardised DR-TB treatment regimen at two outpatient, decentralized, public-sector sites in Johannesburg, South Africa.
Why are some children unresponsive to adequate treatment for pneumonia, malnutrition, and HIV? Why do some of them die? Maybe they are among the over 600,000 children that fall ill with tuberculosis each year but are never diagnosed.
Join experts from the TB and MNCH communities in a global debate on the linkages between tuberculosis and maternal and child health to:
identify opportunities for intervention,
increase the visibility of childhood TB, and